{"id":"enbrel-liquid","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions (erythema, itching, pain)"},{"rate":"29","effect":"Upper respiratory tract infections"},{"rate":"17","effect":"Headache"},{"rate":"7","effect":"Dizziness"},{"rate":"2-3","effect":"Serious infections (including tuberculosis)"},{"rate":"15-20","effect":"Autoimmune phenomena (anti-dsDNA antibodies)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enbrel (etanercept) is a soluble TNF receptor p75-Fc fusion protein that acts as a TNF inhibitor by binding circulating TNF-alpha and TNF-beta, preventing their interaction with cell surface TNF receptors. This blocks the inflammatory cascade mediated by TNF, reducing systemic inflammation and immune activation in autoimmune conditions. The liquid formulation provides an alternative to the lyophilized powder for subcutaneous injection.","oneSentence":"Enbrel is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving autoimmune and inflammatory diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:54.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT04345458","phase":"PHASE3","title":"Safety and Efficacy Study of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2014-03-06","conditions":"Ankylosing Spondylitis","enrollment":640},{"nctId":"NCT01901185","phase":"PHASE3","title":"Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-11","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":77},{"nctId":"NCT01731457","phase":"PHASE2","title":"Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2011-04","conditions":"Transplanted Kidney Ischemia Reperfusion Injury","enrollment":94},{"nctId":"NCT01894412","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2013-07","conditions":"Healthy","enrollment":48},{"nctId":"NCT02799498","phase":"PHASE1","title":"Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-10","conditions":"Healthy Men and Women","enrollment":36},{"nctId":"NCT02588534","phase":"PHASE1","title":"Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08","conditions":"Healthy Men and Women","enrollment":36},{"nctId":"NCT00110903","phase":"PHASE3","title":"Treatment for Subjects With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00249041","phase":"PHASE3","title":"Enbrel Liquid Immunogenicity Protocol","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":447}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Enbrel liquid","genericName":"Enbrel liquid","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enbrel is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}